131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This is an open label, single arm, parallel-group, multicentre, and dose finding study to
evaluate the safety of ascending radioactive dose levels of 131I-TLX101 administered
intravenously in combination with best standard of care in newly diagnosed GBM patients.